

	September 30, 2026		December 31, 2025
Equity method - performance allocations	$	8,211,947	$	7,309,239
Equity method - capital interests (includes assets pledged of $389,633 and $521,124 as of September 30, 2026 and December 31, 2025, respectively)	1,296,486		1,801,436
Equity investments	613,558		—
Loan held for sale	59,326		—
Investments held to maturity, at amortized cost (includes assets pledged of $72,072 and $82,198 as of September 30, 2026 and December 31, 2025, respectively)	79,550		88,480


Equity method - other	16,943		12,661
Total investments	$	10,277,810	$	9,211,816

Net gains (losses) from performance allocations and capital interests are disclosed in the Revenue section of Note 2 to the Condensed Consolidated Financial Statements. The following table summarizes net gains (losses) from investment activities (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025


Net (losses) gains of equity method investments - other	$	(153)	$	(133)	$	2,593	$	(656)
Net gains from equity investments	121,144		—		108,214		217
Net gains (losses) of investments held for sale and other	—		345		—		(2,227)
Total net gains (losses) from investment activities	$	120,991	$	212	$	110,807	$	(2,666)

As of September 30, 2026, the Company held a short-term funding arrangement as part of the Company’s capital markets activities for $59.3 million which is recorded at amortized cost basis in investments on the Condensed Consolidated Statements of Financial Condition. As of December 31, 2025, there was no outstanding balance on the arrangement.

The carrying value of investments held to maturity is included in investments on the Condensed Consolidated Statements of Financial Condition. The Company estimates an allowance for credit losses (“ACL”) on the investments classified as held to maturity securities. The fair value of investments held to maturity, excluding any reserves for credit losses, was $81.9 million and $90.0 million at September 30, 2026 and December 31, 2025, respectively.

The Company evaluates its equity method investments in which it has not elected the fair value option for impairment whenever events or changes in circumstances indicate that the carrying amounts of such investments may not be recoverable. During the three and nine months ended September 30, 2026 and 2025, the Company did not recognize any impairment losses on an equity method investment.

On February 11, 2026, the Company entered into a long-term, strategic investment management partnership (the “Jackson Transaction”) with Jackson Financial Inc. (“Jackson”) whereby the Company will serve as an investment manager for select general account assets of subsidiaries of Jackson. In connection with the Transaction, the TPG Operating Group purchased 4,715,554 shares of common stock of Jackson. The fair value of the shares purchased is included in Investments on the Condensed Consolidated Statements of Financial Condition and, as the shares purchased have a readily determinable fair value, changes in fair value are recorded within net gains (losses) from investment activities in the Company’s Condensed Consolidated Statements of Operations each reporting period.